Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials

被引:56
作者
Qi, Wei-Xiang [1 ]
Sun, Yuan-Jue [1 ]
Shen, Zan [1 ]
Yao, Yang [1 ]
机构
[1] Shanghai Jiao Tong Univ, Dept Oncol, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China
关键词
Non-small-cell lung cancer; Interstitial lung disease; Erlotinib; Gefitinib; Afatinib; Meta-analysis; EPIDERMAL-GROWTH-FACTOR; ERLOTINIB MAINTENANCE THERAPY; DOUBLE-BLIND; JAPANESE PATIENTS; OPEN-LABEL; 1ST-LINE TREATMENT; 2ND-LINE TREATMENT; FACTOR RECEPTOR; PLUS GEMCITABINE; UNITED-STATES;
D O I
10.1179/1973947814Y.0000000189
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To assess the risk of interstitial lung disease (ILD) with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib, erlotinib, and afatinib. Method: PubMed databases were searched for relevant articles. Statistical analyses were conducted to calculate the summary incidence, odds ratio (OR), and 95% confidence intervals (CIs) by using either random-effects or fixed-effect models. Results: The incidence of all-grade and high-grade (>= grade 3) ILD associated with EGFR-TKIs was 1.6% (95% CI, 1.0-2.4%) and 0.9% (95% CI, 0.6%-1.4%), with a mortality of 13.0% (95% CI, 7.6-21.6%). Patients treated with EGFR-TKIs had a significantly increased risk of developing all-grade (OR, 1.74; 95% CI, 1.25-2.43; P=0.001) and high-grade (OR, 4.38; 95% CI, 2.18-8.79; P<0.001) ILD. No significant difference in the risk of ILD was found in sub-group analysis according to EGFR-TKIs, percentage of EGFR mutation, study location, EGFR-TKIs-based regimens, and controlled therapy. Conclusions: Treatment with EGFR-TKIs is associated with a significantly increased risk of developing ILD.
引用
收藏
页码:40 / 51
页数:12
相关论文
共 83 条
  • [1] AIDA S, 1994, RESPIRATION, V61, P161
  • [2] Interstitial Lung Disease Associated with Gefitinib in Japanese Patients with EGFR-mutated Non-small-cell Lung Cancer: Combined Analysis of Two Phase III Trials (NEJ 002 and WJTOG 3405)
    Akamatsu, Hiroaki
    Inoue, Akira
    Mitsudomi, Tetsuya
    Kobayashi, Kunihiko
    Nakagawa, Kazuhiko
    Mori, Keita
    Nukiwa, Toshihiro
    Nakanishi, Yoichi
    Yamamoto, Nobuyuki
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (06) : 664 - 668
  • [3] Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
    Ando, M
    Okamoto, I
    Yamamoto, N
    Takeda, K
    Tamura, K
    Seto, T
    Ariyoshi, Y
    Fukuoka, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) : 2549 - 2556
  • [4] [Anonymous], CTC V 2 0 COMM TERM
  • [5] Aoe K, 2005, ANTICANCER RES, V25, P415
  • [6] American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer
    Azzoli, Christopher G.
    Baker, Sherman, Jr.
    Temin, Sarah
    Pao, William
    Aliff, Timothy
    Brahmer, Julie
    Johnson, David H.
    Laskin, Janessa L.
    Masters, Gregory
    Milton, Daniel
    Nordquist, Luke
    Pfister, David G.
    Piantadosi, Steven
    Schiller, Joan H.
    Smith, Reily
    Smith, Thomas J.
    Strawn, John R.
    Trent, David
    Giaccone, Giuseppe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : 6251 - 6266
  • [7] OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS
    BEGG, CB
    MAZUMDAR, M
    [J]. BIOMETRICS, 1994, 50 (04) : 1088 - 1101
  • [8] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
    Cappuzzo, Federico
    Ciuleanu, Tudor
    Stelmakh, Lilia
    Cicenas, Saulius
    Szczesna, Aleksandra
    Juhasz, Erzsebet
    Esteban, Emilio
    Molinier, Olivier
    Brugger, Wolfram
    Melezinek, Ivan
    Klingelschmitt, Gaelle
    Klughammer, Barbara
    Giaccone, Giuseppe
    [J]. LANCET ONCOLOGY, 2010, 11 (06) : 521 - 529
  • [9] Gefitinib: an adverse effects profile
    Cersosimo, Robert J.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2006, 5 (03) : 469 - 479
  • [10] Gefitinib-Related Interstitial Lung Disease in Taiwanese Patients With Non-Small-Cell Lung Cancer
    Chang, Shih-Chieh
    Chang, Cheng-Yu
    Chang, Shu-Ju
    Yuan, Mei-Kang
    Lai, Yi-Chun
    Liu, Yu-Chang
    Chen, Cheng-Yu
    Kuo, Li-Chiao
    Yu, Chong-Jen
    [J]. CLINICAL LUNG CANCER, 2013, 14 (01) : 55 - 61